Here are the latest quarterly results of Piramal Enterprises. For more details, see the Piramal Enterprises financial fact sheet and Piramal Enterprises share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 34,891 | 36,797 | 35,063 | 36,036 | 38,057 | 33,410 | 29,373 | 33,018 | |
Other income | Rs m | 1,028 | 852 | 669 | 627 | 1,413 | 2,396 | 655 | 376 | |
Turnover | Rs m | 35,919 | 37,649 | 35,732 | 36,662 | 39,470 | 35,806 | 30,028 | 33,394 | |
Expenses | Rs m | 14,618 | 17,380 | 14,004 | 13,497 | 15,099 | 34,386 | 11,419 | 13,019 | |
Gross profit | Rs m | 20,273 | 19,283 | 20,945 | 22,398 | 22,958 | -976 | 17,955 | 20,395 | |
Depreciation | Rs m | 1,326 | 1,354 | 1,582 | 1,664 | 1,664 | 1,429 | 1,346 | 1,394 | |
Interest | Rs m | 11,688 | 13,157 | 14,085 | 14,182 | 14,417 | 12,953 | 11,046 | 11,558 | |
Profit before tax | Rs m | 8,287 | 5,624 | 5,947 | 7,179 | 8,289 | -12,962 | 6,217 | 7,819 | |
Tax | Rs m | 2,930 | 2,243 | 2,176 | 1,581 | 2,306 | 12,595 | 1,611 | 2,039 | |
Profit after tax | Rs m | 5,356 | 3,381 | 3,771 | 5,598 | 5,983 | -25,557 | 4,606 | 5,781 | |
Gross profit margin | % | 58.1 | 52.4 | 59.7 | 62.2 | 60.3 | -2.9 | 61.1 | 61.8 | |
Effective tax rate | % | 35.4 | 39.9 | 36.6 | 22.0 | 27.8 | -97.2 | 25.9 | 26.1 | |
Net profit margin | % | 15.4 | 9.2 | 10.8 | 15.5 | 15.7 | -76.5 | 15.7 | 17.5 | |
Diluted EPS | Rs | 23.7 | 15.0 | 16.7 | 24.8 | 26.5 | -113.3 | 20.4 | 25.6 | |
Diluted EPS (TTM) | Rs | 214.2 | 54.3 | 76.8 | 80.3 | 83.1 | -45.2 | -41.5 | -40.7 | |
![]() |
Read: Piramal Enterprises 1QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: LUPIN INDOCO REMEDIES DISHMAN PHARMA PANACEA BIOTECH GSK PHARMA
Compare PIRAMAL ENTERPRISES With: LUPIN INDOCO REMEDIES DISHMAN PHARMA PANACEA BIOTECH GSK PHARMA
Compare PIRAMAL ENTERPRISES With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More